| Name | Title | Contact Details |
|---|
Curaleaf Holdings, Inc. is the leading vertically integrated multi-state cannabis operator in the United States.The company is positioned in highly populated, limited license states, and currently operates in 12 states with 44 dispensaries, 12 cultivation sites and 11 processing sites.
North Carolina Mutual Drug Company is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
Founded in 2003, Valeo Pharma is a Canadian Pharma Company with a long history of successfully driving #healthcareinnovationforcanadians by commercializing pharmaceutical products in Canada and is therapeutically focused on respiratory diseases, neurodegenerative diseases, specialty products, and oncology.
Vitality has developed a new class of cannabinoid prodrugs (cannabosides), which enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable potent local therapeutic effects while reducing or avoiding the systemic delivery of THC to the brain. Currently, the psychoactivity of THC limits the dose of cannabinoids that can be used for treatment of pain and inflammation. Studies have shown that the cannabinoid system is a potent mediator of pain relief and inflammation, as studies have shown that cannabinoid drugs can in some cases be far more potent than opiates for pain relief, and far more potent than aspirin or corticosteroids for providing anti-inflammatory effects. For example, cannabinoid drugs have been shown to be nearly 10 times as potent as morphine for neuropathic pain relief. Studies have also shown they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation. But currently, the “elephant in the room” remains, which is that the desired potent effects cannot be achieved when high doses of THC enter the bloodstream and brain. Patients are forced to limit their doses, so targeted administration is critical. Our solution goes to the heart of this issue and offers an alternative means to increase the beneficial dosage, right at the site of disease – where it matters most, and relegates the psychoactive nature of the drug to a manageable side effect.